TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial - Sinn, M; Sinn, BV; Treue, D (Clin Cancer Res, 2020)
et al.